Skip To Main Content
Yair Lotan on Muck Rack

Yair Lotan

As seen in: Nature, Wiley, Wiley Online Library, ScienceDirect, The Lancet, Future Medicine, OncLive, European Urology, EMJ- European Medical Journal, UroToday and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yair

Contact Yair, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

|
By Patrick J. Hensley, Jeremy Y. C. Teoh, Roger Li, Shilpa Gupta, Laura Bukavina, Kent W. Mouw, Niyati Lobo, Brigida Anna Maiorano, Wei Shen Tan, Piyush Agarwal, Hikmat Al-Ahmadie, Trinity J. Bivalacqua, Thomas W. Flaig, Charles C. Guo, Amir Horowitz, Wassim Kassouf, Max Kates, Badrinath R. Konety, Janet B. Kukreja, Yair Lotan, David J. McConkey, Laura Mertens, Maria Carmen Mir, Marco Moschini, Andrea Necchi, Karima Oualla, Vignesh T. Packiam, Bogdana Schmidt, Roger Buckley, Ashish M. Kamat
| Nature Verified
Abstract Crucial unmet needs for standardization and clinical integration of actionable biomarkers persist across the bladder cancer disease spectrum. To address these gaps, the International Bladder Cancer Group (IBCG) convened a global multidisciplinary panel to develop evidence-based consensus recommendations on biomarker use in bladder cancer. Recommendations were formulated across the disease spectrum using a modified Delphi process.
Open in Who Shared Issue with article?

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

|
By Yair Lotan, Michael Luu, Menghan Liu
| UroToday Verified
More than 50% of patients with non-muscle invasive bladder cancer (NMIBC) experience recurrence, requiring lifelong surveillance with repeated cystoscopy. Given the invasive nature and cost of cystoscopy, accurate non-invasive tools are needed to support risk-adapted monitoring. We evaluated the ability of Oncuria-Monitor to detect recurrent bladder cancer (BC) during surveillance.
Open in Who Shared Issue with article?

Active surveillance in low-grade NMIBC — results of an international two-round modified Delphi consensus

|
By Roberto Contieri, Paolo Gontero, Rodolfo Hurle, Luca Afferi, Simone Albisinni, Marek Babjuk, Alison Birtle, Peter Black, Maurizio Brausi, Otakar Capoun, Albert Carrion, James Catto, Ananya Choudhury, Alessia Cimadamore, Eva M. Compérat, Siamak Daneshmand, David D’Andrea, Francesco Del Giudice, Patrick J. Hensley, Wojciech W. Krajewski, Ekaterina Laukhtina, Roger Li, Fredrik Liedberg, Yair Lotan, Gautier Marcq, Paramananthan Mariappan, Andrea Mari Verified, Alberto Martini, Richard P. Meijer, Maria Carmen Mir, Keiichiro Mori, Marco Moschini, Hugh Mostafid, Joan Palou, Valeria Panebianco, Sisto Perdonà, Sima Porten, Sarah P. Psutka, Michael Rink, Morgan Rouprêt, Thomas Seisen, Mark Soloway, Viktor Soukup, Gary D. Steinberg, Arnulf Stenzl, Karl H. Tully, Toine Van der Heijden, Toine van der Heijden, Bas W. G. van Rhijn, Alfred Witjes, Evanguelos Xylinas, Ashish M. Kamat, Benjamin Pradere, Laura Mertens, Max Bruins, Alexandra Masson Lecomte, Micheal O’Donnell, Jeremy YC Teoh
| Nature Verified
Abstract Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients.
Open in Who Shared Issue with article?
See all 49 licensed articles (54 Total)